New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Bone and Connective Tissue Cancer
Risk for Adverse Events Up With Low-Dose Methotrexate
Risks increased for skin cancer and GI, pulmonary, infectious, hematologic adverse events
Strontium89 Now Available for Relief of Metastatic Bone Pain
Strontium89 (Strontium Chloride Sr-89 injection), a radiopharmaceutical indicated for the relief of bone pain in patients with painful skeletal metastases, has been made available by Q BioMed.
Tazverik Gets FDA Approval for Epithelioid Sarcoma
The FDA has granted accelerated approval to Tazverik™ (tazemetostat tablets; Epizyme) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Belantamab Mafodotin Gets Priority Review for Heavily Pretreated Multiple Myeloma
The FDA has granted Priority Review to the Biologics License Application (BLA) of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
New Drug Product: Rozlytrek
This slideshow shows drug information for Rozlytrek. Click here for the complete Rozlytrek monograph.
FDA Approves New Darzalex Combo Regimen for Multiple Myeloma
The approval was based on data from a phase 3 study which compared induction and consolidation treatment with Darzalex in combination with bortezomib, thalidomide and dexamethasone to treatment with bortezomib, thalidomide, and dexamethasone.
Breakthrough Therapy Granted to Desmoid Tumor Treatment
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for nirogacestat (SpringWorks Therapeutics) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.
New Drug Product: Turalio
This slideshow reviews drug information for Turalio. Click here for the complete Turalio monograph. For a downloadable PDF of this slideshow, click here.
Novel Therapy Treats Triple-Class Refractory Multiple Myeloma
Partial response or better observed in 26 percent of patients receiving oral selinexor-dexamethasone
